Nanoparticle synthesis depends on the knowledge and tools to get the job done right. NYACOL offers both. Learn about our diverse nanomaterial products.

Applied Plastics is a leader in advanced catheter components including the trademarked PTFE Natural® coating applied to fine wire, forming & extrusion mandrels and pull wires.  Visit our NEW online store to purchase in stock coated mandrels, wires & hypotubes, product ships within 24 hours. For over 65 years, our lubricious and robust coatings, with tolerances held to +/- .0003”, provide the highest level of bond strength & durability to withstand the high temperatures required while manufacturing advanced catheter systems. Our smooth, lubricious coated fine wire, mandrels and hypotubes enable faster and higher quality catheter production and allow for improved navigation through the body’s tortuous anatomies. As more advanced devices are used in increasingly complex interventional procedures, medical device companies require the highest quality of PTFE coating and seek out Applied Plastics’ capabilities. Applied Plastics’ customers include the leading medical device OEMs and contract manufacturers focused on the high growth and innovative vascular catheter device market including therapy areas ranging from cardiac rhythm management (CRM), electrophysiology (EP), neurovascular, peripheral vascular and structural heart. Applied Plastics became a portfolio company of Vance Street Capital in January 2019.

American Durafilm® Co., Inc. has more than 60 years of experience in providing solutions for wide-range of applications requiring high performance films, coating, and tubing. Founded in 1949 as one of the three original Licensed Industrial Applicators of Teflon® brand coatings, over half a century later, the company remains a leading supplier of DuPont™ ultra-high performance films, including Kapton®, Teflon®, and Tefzel®. The company is as well known for its responsive service as for its high quality products, having received numerous awards from commercial and government customers for on-time performance. Major functions of fabrication including heat sealing and assembly work which can be performed onsite in their updated 1000 square foot, ISO 7/Class 10000 clean room facilities. American Durafilm® is a national stocking distributor of Teflon®, Kapton®, and Tefzel® films as well as FEP rollcovers. The film thicknesses range from .0005” to .020”. In addition to seamless polyimide tubing in ID sizes ranging from 0.005” up to 6”, ISO 9001: 2008 certified Tubing Division provides laser machining, cut to length, necking, flaring, tipping, thermoplastic jackets, reflow and subassembly services capabilities. American Durafilm® can also fabricate all of these high performance films according to customer specifications including processes for thermoforming, heat sealing, and die cutting.

Alcresta Therapeutics is dedicated to developing and commercializing novel, enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency or fat malabsorption, which results in malabsorption common in cystic fibrosis, digestive cancers, preterm birth, and other serious diseases. The company’s lead product, RELiZORB®, is designed to reliably and efficiently deliver the optimal nutritional and caloric benefit from existing enteral feeding formulas by improving the breakdown and absorption of fats, in particular long-chain polyunsaturated fatty acids like omega-3 (including DHA, EPA). RELiZORB is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula. The company’s platform is supported by our extensive experience in pharmaceutical, medical device and nutritional product development. Based in Massachusetts, the company is backed by top-tier venture investors Athyrium Capital Management, Bessemer Venture Partners, Frazier Healthcare, and Third Rock Ventures.

Xtalic creates performance breakthroughs using our proprietary Dynamic Nanostructure Control® to custom tailor unique Nanostructured metal alloys to deliver new levels of performance, reduce use of high cost raw materials and replace toxic or unsafe materials.

Camger Coatings Systems, Inc. has been designing and manufacturing specialty coatings and adhesives in New England for more than 50 years. Our products fulfill a broad array of applications including, but not limited to, high end architectural, fine wood finishing, DTM protective, and marine coatings. We also offer contract manufacturing services to companies that would like to outsource the production of their product. We are proudly a privately owned, family oriented, people focused business. Our customers say that our greatest strengths are the quality of our products and the quality of our customer service. Come be a part of what's happening at Camger!

HYPERION CATALYSIS INTERNATIONAL is an electrical/electronic manufacturing company based out of 38 Smith Pl, Cambridge, MA, United States.

Our team ‘brings it’ every day for one mission: to conquer transcription factors and create cutting-edge medicines for patients. Flare Therapeutics is lighting up a new therapeutic space with an entirely different approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of our scientific founders, the FlareTx team is leveraging the power of ‘switch sites’ as druggable regions that hold the control for predictable and profound changes in DNA transcription, and therefore, gene expression. Our drug discovery to target ‘switch sites’ has rapidly advanced, resulting in our pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology.

We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.

Served as a bioinformatics/genomics consultant for natural product discovery from exotic soil bacteria where I advised whole-genome sequencing and secondary metabolite bioinformatic efforts. Interfaced heavily with chemistry and biology teams to characterize both new strains and novel antibiotic compounds.

Transforming the right molecules into the best medicines™ Boston Pharmaceuticals acquires and transforms innovative molecules into differentiated medicines that improve patients’ lives. We have rapidly built a portfolio of high-value candidates across multiple therapeutic areas and are actively seeking additional programs for our diverse pipeline.